Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $248.2M | $242.0M | $267.8M | $321.5M | $348.9M | $418.6M |
| Gross profit | $208.9M | $202.4M | $219.5M | $266.8M | $288.8M | $345.6M |
| Operating income | -$45.4M | -$7.1M | -$14.7M | $37.1M | $58.9M | $63.9M |
| Net income | -$49.3M | -$10.3M | -$30.2M | $58.2M | $42.4M | $48.6M |
| Diluted EPS | -$0.77 | -$0.15 | -$0.33 | $0.37 | $0.28 | $0.32 |
| Operating cash flow | -$30.3M | -$2.0M | -$17.9M | $26.8M | $66.2M | $74.0M |
| Free cash flow | — | -$5.2M | -$19.4M | $24.8M | — | — |
| Gross margin | 84.2% | 83.6% | 82.0% | 83.0% | 82.8% | 82.6% |
| Operating margin | -18.3% | -2.9% | -5.5% | 11.5% | 16.9% | 15.3% |
| Net margin | -19.9% | -4.2% | -11.3% | 18.1% | 12.2% | 11.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $87.2M | $84.1M | $92.9M | $88.2M | $98.6M | $113.7M | $118.1M | $59.0M |
| Gross profit | $72.4M | $68.7M | $76.0M | $71.6M | $79.9M | $95.0M | $99.0M | $41.6M |
| Operating income | $23.4M | $11.2M | $11.1M | $8.3M | $12.4M | $22.2M | $21.1M | -$16.0M |
| Net income | $17.6M | $8.1M | $7.4M | $7.0M | $9.6M | $16.7M | $15.2M | -$10.9M |
| Diluted EPS | $0.12 | $0.05 | $0.05 | $0.05 | $0.06 | $0.11 | $0.10 | -$0.07 |
| Operating cash flow | $21.8M | $19.6M | $18.8M | $5.3M | $14.4M | $29.3M | $25.0M | $1.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 83.0% | 81.8% | 81.8% | 81.2% | 81.1% | 83.5% | 83.9% | 70.6% |
| Operating margin | 26.9% | 13.3% | 11.9% | 9.4% | 12.5% | 19.5% | 17.8% | -27.2% |
| Net margin | 20.2% | 9.6% | 8.0% | 8.0% | 9.8% | 14.7% | 12.9% | -18.4% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | DOUG RICE· Chief Financial Officer | Tax withholding | 12,749 | $3.95 | $50,358.55 | filing |
| 2026-06-24 | Maersk-Moller Kimberly· Chief Commercial Officer | Tax withholding | 19,820 | $3.83 | $75,910.60 | filing |
| 2026-06-10 | BIERMAN JAMES L | Award | 50,913 | $3.64 | $185,323.32 | filing |
| 2026-06-10 | PUHY DOROTHY E | Award | 50,913 | $3.64 | $185,323.32 | filing |
| 2026-06-10 | Newton Todd | Award | 50,913 | $3.64 | $185,323.32 | filing |
| 2026-06-10 | HAWKINS WILLIAM A | Award | 50,913 | $3.64 | $185,323.32 | filing |
| 2026-06-10 | Olson Tiffany | Award | 50,913 | $3.64 | $185,323.32 | filing |
| 2026-03-13 | Hulse William Frank IV· General Counsel and CAO | Tax withholding | 20,245 | $4.38 | $88,673.10 | filing |
| 2026-03-13 | Maersk-Moller Kimberly· Chief Commercial Officer | Tax withholding | 6,762 | $4.38 | $29,617.56 | filing |
| 2026-03-10 | DOUG RICE· Chief Financial Officer | Option exercise | 243,000 | $4.50 | $1.1M | filing |
| 2026-03-10 | Hulse William Frank IV· General Counsel and CAO | Option exercise | 136,364 | $4.50 | $613,638.00 | filing |
| 2026-03-10 | DOUG RICE· Chief Financial Officer | Tax withholding | 96,363 | $4.50 | $433,633.50 | filing |
| 2026-03-10 | Hulse William Frank IV· General Counsel and CAO | Tax withholding | 61,460 | $4.50 | $276,570.00 | filing |
| 2026-03-10 | Maersk-Moller Kimberly· Chief Commercial Officer | Option exercise | 42,845 | $4.50 | $192,802.50 | filing |
| 2026-03-10 | Maersk-Moller Kimberly· Chief Commercial Officer | Tax withholding | 21,270 | $4.50 | $95,715.00 | filing |
| 2026-03-04 | Capper Joseph H· Chief Executive Officer | Award | 371,094 | $0.00 | $0.00 | filing |
| 2026-03-04 | DOUG RICE· Chief Financial Officer | Award | 74,163 | $0.00 | $0.00 | filing |
| 2026-03-04 | Hulse William Frank IV· General Counsel and CAO | Award | 74,987 | $0.00 | $0.00 | filing |
| 2026-03-04 | Whitlow Ricci S· Chief Operating Officer | Award | 74,163 | $0.00 | $0.00 | filing |
| 2026-03-04 | Maersk-Moller Kimberly· Chief Commercial Officer | Award | 74,163 | $0.00 | $0.00 | filing |
| 2026-02-13 | Whitlow Ricci S· Chief Operating Officer | Tax withholding | 61,961 | $5.12 | $317,240.32 | filing |
| 2025-11-06 | Maersk-Moller Kimberly· Chief Commercial Officer | Sale | 58,300 | $7.42 | $432,329.48 | filing |
| 2025-07-03 | DOUG RICE· Chief Financial Officer | Tax withholding | 12,749 | $6.34 | $80,828.66 | filing |
| 2025-06-24 | Maersk-Moller Kimberly· Chief Commercial Officer | Tax withholding | 12,034 | $5.96 | $71,722.64 | filing |
| 2025-06-18 | BEHRENS M KATHLEEN | Award | 28,609 | $6.47 | $185,100.23 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.